Andrea Hittle
Family · Rushville, INNPI 1669051009
Payments from drug & device makers
Across 154 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$624
- Pfizer$339
- Otsuka America Pharmaceutical, Inc.$262
- Lilly USA, LLC$178
- AstraZeneca$148
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$145
- plus $890 from 19 others
What the payments were for
- Food & beverage$2,587100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $624 |
| Pfizer | 22 | $339 |
| Otsuka America Pharmaceutical, Inc. | 22 | $262 |
| Lilly USA, LLC | 10 | $178 |
| AstraZeneca | 5 | $148 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $145 |
| Novo Nordisk | 7 | $109 |
| Vanda Pharmaceuticals Inc. | 5 | $103 |
| Exact Sciences | 5 | $85 |
| Amgen | 5 | $82 |
| Lundbeck LLC | 4 | $73 |
| Astellas Pharma US Inc | 3 | $65 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Neurocrine Biosciences, Inc. | 3 | $53 |
| GSK | 3 | $42 |
| Boehringer Ingelheim | 2 | $39 |
| Bayer | 2 | $30 |
| Inari Medical, Inc. | 1 | $27 |
| Verona Pharma, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Corium, LLC | 1 | $16 |
| Organon | 1 | $14 |
How this compares
$2,587 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 33 | $33,072 |
| OzempicSemaglutide | 24 | $21,440 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $15,841 |
| Spiriva HandihalerTiotropium Bromide | 14 | $11,262 |
| JanuviaSitagliptin Phosphate | 13 | $7,537 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,211 |
| Omeprazole | 87 | $1,473 |
| Duloxetine Hcl | 44 | $1,241 |
| Pregabalin | 22 | $1,235 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,217 |
| Fluoxetine Hcl | 25 | $1,175 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $1,169 |
| Pantoprazole Sodium | 115 | $1,152 |
| Rosuvastatin Calcium | 60 | $1,110 |
| Celecoxib | 27 | $1,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $178 | $33,07233 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $42 | $22,05338 claims |
| Novo NordiskOzempic | $109 | $21,44024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.
Other family in Rushville
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.